Drug Profile
Research programme: selective estrogen receptor modulators - Johnson & Johnson
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Johnson & Johnson
- Class Benzopyrans
- Mechanism of Action Selective estrogen receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Postmenopausal osteoporosis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Postmenopausal-osteoporosis in USA
- 21 Aug 2008 Preclinical trials in Postmenopausal osteoporosis in USA (unspecified route)